Fig. 6

Both COVID-19 and NMDAR Antagonist Pre-treatment Modulate Microglial Response. IBA1 fluorescent (FL) Intensity. Data points are representative of sections in pons and medulla. (a) Images of sections representing immunofluorescent staining for IBA1 from the medulla of a COVID-19 negative brain and COVID-19 positive brain from each key treatment group. Key groups include those sacrificed 10 days post-inoculation. (b) IBA1 FL intensity of subjects negative for COVID-19 according to drug treatment. All animals were sacrificed 10 days post-virus inoculation. N = 9–16 sections per group. (c) IBA1 FL intensity of COVID-19 Positive Saline treated subjects over time. N = 12–17 sections per group. (d) IBA1 FL intensity of COVID-19 Positive Memantine treated subjects over time. N = 7–10 sections per group. (e) IBA1 FL intensity of COVID-19 Positive Ifenprodil treated subjects over time. N = 9–17 sections per group. All results reported as mean FL intensity + /− S.E.M. with *p < 0.05 and **p < 0.01 as shown, ## < 0.01 respective to COVID-19 Positive Saline Day 10, and & < 0.05 respective to COVID-19 Positive Memantine Day 10.